Goldman Sachs Rates MoonLake Immunotherapeutics Neutral for Sonelokimab Market Potential
Tuesday, 2 April 2024, 15:21
Goldman Sachs Neutral Rating on MoonLake Immunotherapeutics
Goldman Sachs has initiated coverage of MoonLake Immunotherapeutics (MLTX) with a neutral rating, citing the market potential of the company's lead drug, sonelokimab. The analysis delves into the implications of this rating on MoonLake's future performance in the pharmaceutical market. While sonelokimab shows promise, the neutral rating suggests a cautious outlook for investors.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.